Tag: NCT02715284

Home / NCT02715284

Categories

Dostarlimab-gxly receives accelerated approval from the FDA for dMMR advanced solid tumours

August 2021: Dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) was given accelerated approval by the Food and Drug Administration for adult patients with mismatch repair deficient (dMMR) recurrent or a...
nct02715284

Scan the code